Evaluación cualitativa de impacto de un programa de producción pública de medicamentos biosimilares en Santa Fe
Fecha
2016-08-26
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Resumen
INTRODUCCIÓN: Los biosimilares tendrían igual indicación terapéutica y menores
costos de desarrollo que los biofármacos originales. Aumentando su oferta mejoraría la
eficiencia y accesibilidad, pero en Argentina este mercado define precios iguales o superiores a las drogas originales. Una alternativa sería incentivar la oferta desde la producción pública, basada en desarrollos científicos institucionales existentes en Santa Fe, con sinergias entre empresas incubadas en la Universidad Nacional del Litoral y el Laboratorio Industrial Farmacéutico para abastecer al Ministerio de Salud y la Obra Social Provincial.
OBJETIVO: Evaluar cualitativamente el impacto potencial del desarrollo de un
programa de medicamentos biosimilares articulado en la producción pública, desde una
perspectiva de factibilidad presupuestaria, de sinergia institucional, de accesibilidad
prestacional y de regulación de mercado.
MÉTODOS: La propuesta se encuadra en un estudio de evaluación cualitativa,
basado en herramientas de recolección de datos subjetivos primarios. Reviste carácter tanto descriptivo como propositivo, en relación a las posibilidades de sinergia institucional entre las entidades descriptas, como también de las condiciones de articulación actual de cobertura y los efectos potenciales del proyecto sobre el mercado de biofármacos.
RESULTADOS: Los sectores público, seguridad social y académico/científico
estimaron posible la implementación de estas sinergias con distintos ajustes, con potencial impacto en la accesibilidad y el mercado, mientras que el sector privado desestimó su real alcance.
CONCLUSIONES: Con excepción del sector privado, los demás revelaron cualitativamente un impacto positivo de la propuesta estudiada
INTRODUCTION: Biosimilars would like therapeutic and lower development costs than the original indication biopharmaceuticals. Increasing this offer would improve efficiency and accessibility, but in Argentina this market defined at or above the original drug prices. An alternative would motivate supply from public production, based on existing institutional scientific developments in Santa Fe, with synergies between companies incubated at the Universidad Nacional del Litoral and the Pharmaceutical Industrial Laboratory to supply the Ministry of Health and the provincial Social Work. .OBJECTIVE: Qualitatively evaluating of the potential of developing a biosimilar program articulated in public production impact from the perspective of budgetary feasibility, institutional synergy, accessibility and performance based market regulation. . METHODS The proposal begins of a study of qualitative assessment tools based on primary subjective data collection. It will be a descriptive and a va el otro adjetivo in relation both to the possibilities of institutional synergy between the entities described before, as well as the conditions as current joint coverage and the potential effects of the project on the market for biopharmaceuticals. RESULTS: The public academic / scientific sectors, and social security space considered it possible to implement these synergies with different settings, with potential impact on the accessibility to the market, while the private sector dismissed its real scope. CONCLUSIONS: With the exception of the private sector, other qualitatively showed, a positive impact of the proposed study
INTRODUCTION: Biosimilars would like therapeutic and lower development costs than the original indication biopharmaceuticals. Increasing this offer would improve efficiency and accessibility, but in Argentina this market defined at or above the original drug prices. An alternative would motivate supply from public production, based on existing institutional scientific developments in Santa Fe, with synergies between companies incubated at the Universidad Nacional del Litoral and the Pharmaceutical Industrial Laboratory to supply the Ministry of Health and the provincial Social Work. .OBJECTIVE: Qualitatively evaluating of the potential of developing a biosimilar program articulated in public production impact from the perspective of budgetary feasibility, institutional synergy, accessibility and performance based market regulation. . METHODS The proposal begins of a study of qualitative assessment tools based on primary subjective data collection. It will be a descriptive and a va el otro adjetivo in relation both to the possibilities of institutional synergy between the entities described before, as well as the conditions as current joint coverage and the potential effects of the project on the market for biopharmaceuticals. RESULTS: The public academic / scientific sectors, and social security space considered it possible to implement these synergies with different settings, with potential impact on the accessibility to the market, while the private sector dismissed its real scope. CONCLUSIONS: With the exception of the private sector, other qualitatively showed, a positive impact of the proposed study
Descripción
Palabras clave
Biosimilares Farmacéuticos, Salud Pública, Economía de la Salud